Terms ending in 2033
Interpace Diagnostics Corporation
Every in-force patent on Interpace Diagnostics Corporation's record whose computed term ends in 2033, whoever holds it now. Soonest term end first, then patent number.
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 10,255,410 | Methods for Treating Barrett's Metaplasia and Esophageal Adenocarcinoma In force · High confidence | Interpace Diagnostics Corporation | In force | High confidence | |
| US 12,205,676 | Methods for Treating Barrett's Metaplasia and Esophageal Adenocarcinoma In force · High confidence | Interpace Diagnostics Corporation | In force | High confidence | |
| US 10,131,942 | Methods for Treating Barrett's Metaplasia and Esophageal Adenocarcinoma In force · High confidence | Interpace Diagnostics Corporation | In force | High confidence | |
| US 10,444,239 | Methods for Measuring Carcinoembryonic Antigen In force · Medium confidence | Interpace Diagnostics Corporation | In force | Medium confidence |
4 of 4 patents shown. Soonest term end first, then patent number.
Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.